Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001085146-25-001726
Filing Date
2025-02-14
Accepted
2025-02-14 17:18:26
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7756
  Complete submission text file 0001085146-25-001726.txt   9428
Mailing Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 781-419-1400
Syndax Pharmaceuticals Inc (Subject) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89449 | Film No.: 25630974
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 221 ELM ROAD PRINCETON NJ 08540
Business Address 221 ELM ROAD PRINCETON NJ 08540 212-659-3970
Kynam Capital Management, LP (Filed by) CIK: 0001907884 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A